HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma
HHLA2 acts as an oncogene in HCC by activating c-Met, promoting tumor progression and metastasis. HHLA2 expression correlates with c-Met activation and predicts poor prognosis in HCC patients. Importantly, HHLA2 can serve as a stratification marker for c-Met inhibitor therapy, potentially enabling a personalized approach to improve therapeutic outcomes in this challenging disease.
Authors
- Jiahong Wang
- Jianying Huang (ORCID: https://orcid.org/0000-0003-0515-9523)
- Yuqian Pang
- Silvia Vega-Rubín-de-Celis (ORCID: https://orcid.org/0000-0002-4196-8996)
- Yun Zeng (ORCID: https://orcid.org/0000-0002-5747-3349)
- Josephine Thinwa (ORCID: https://orcid.org/0000-0003-4120-0722)
- Yuting Li (ORCID: https://orcid.org/0009-0008-5686-2140)
- Xiaoyi Huang (ORCID: https://orcid.org/0000-0002-2355-5688)
- Zhe Zhang (ORCID: https://orcid.org/0000-0002-7488-078X)
- Qisheng Zhang (ORCID: https://orcid.org/0000-0002-0899-6856)
- Hao Shen (ORCID: https://orcid.org/0000-0002-8557-8973)
- Feng Shen (ORCID: https://orcid.org/0000-0002-6256-9986)
- Yongjie Wei
- Run-Qian Fang
- Tao Yuan
- Zhao Yao (ORCID: https://orcid.org/0009-0003-5483-4385)
Institutions
- Tongji University (CN)
- Shenzhen University (CN)
- Essen University Hospital (DE)
- Shanghai Electric (China) (CN)
- Shenzhen University Health Science Center (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- The University of Texas Southwestern Medical Center (US)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1186/s13046-025-03407-6
- Citations
- 2
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- National Natural Science Foundation of China